Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buspirone + paroxetine
- Development stage
- Preclinical
- Lead developer
- Mead Johnson Nutrition
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of buspirone and paroxetine used for treating depression and anxiety disorders. Buspirone is an anxiolytic agent that acts as a serotonin 5-HT1A receptor agonist, while paroxetine is a selective serotonin reuptake inhibitor (SSRI). The combination works by affecting serotonin levels in the brain through different mechanisms, potentially providing enhanced therapeutic effects for patients with treatment-resistant depression or anxiety.
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on buspirone + paroxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buspirone + paroxetine.